Research analysts at Cowen and Company raised their target price on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) to $105.00 in a report released on Thursday, StockRatingsNetwork.com reports. The firm currently has an “outperform” rating on the stock. Cowen and Company’s price target would suggest a potential upside of 26.78% from the company’s current price.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 2.85% during mid-day trading on Thursday, hitting $82.82. 832,979 shares of the company’s stock traded hands. Aegerion Pharmaceuticals has a 1-year low of $13.33 and a 1-year high of $101.00. The stock has a 50-day moving average of $86.71 and a 200-day moving average of $73.8. The company’s market cap is $2.399 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last announced its earnings results on Tuesday, October 29th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.07. The company had revenue of $16.30 million for the quarter, compared to the consensus estimate of $13.07 million. Aegerion Pharmaceuticals’s revenue was up 1629900.0% compared to the same quarter last year. Analysts expect that Aegerion Pharmaceuticals will post $-2.10 EPS for the current fiscal year.
In other Aegerion Pharmaceuticals news, CEO Marc D. Beer unloaded 40,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $87.79, for a total value of $3,511,600.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
Several other analysts have also recently commented on the stock. Analysts at FBR & Co. initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating and a $111.00 price target on the stock. Eleven equities research analysts have rated the stock with a buy rating, Aegerion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $92.58.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.